Profile
Sector:
HealthcareIndustry:
Medical Instruments & SuppliesCountry:
United StatesIPO:
21 August 2018Website:
http://www.bionanogenomics.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:59:34 GMTDividend
Analysts recommendations
Institutional Ownership
BNGO Latest News
Healthcare stocks often hold significant potential due to the constant demand for medical advancements. However, not all companies in this sector are poised for growth.
Many investors are giving up on promising stocks that are unlikely to fail, a trend that has been worsened by excessive concerns about rising interest rates.
SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano's president and chief executive officer, will present at TD Cowen's 44th Annual Health Care Conference on March 6, 2024.
SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Tuesday, March 5, 2024, at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and year end 2023 and to highlight recent corporate progress.
Now might be a good time to consider scooping up shares of penny stocks to buy on the dip. However, caution is essential, as penny stocks can be volatile and speculative.
On Wall Street zeroes can become heroes relatively quickly. For example, in the past the Street hated Roku (NASDAQ: ROKU ), Intel (NASDAQ: INTC ), Shopify (NYSE: SHOP ) and Pinterest (NYSE: PINS ) and now they're all among the most beloved names in the stock market.
Bionano Genomics, Inc. (BNGO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Bionano Genomics, Inc. (NASDAQ:BNGO ) Stifel Healthcare Conference Call November 15, 2023 1:50 PM ET Company Participants Erik Holmlin - CEO Conference Call Participants Dan Arias - Stifel Dan Arias Okay. Welcome back to the 2023 Stifel Healthcare Conference Day Two.
In general, stocks generate outsized returns because the Street has been overly bearish on their outlook. Due to the Street's overdone high interest rate concerns, it's now unduly pessimistic about many growth equities with great futures.
Bionano Genomics, Inc. (NASDAQ:BNGO ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants David Holmes - Investor Relations Erik Holmlin - Chief Executive Officer Gülsen Kama - Chief Financial Officer Conference Call Participants Michael Okunewitch - Maxim Group Sung Ji Nam - Scotiabank Jeffrey Cohen - Ladenburg Thalmann Operator Good day, and welcome to the Bionano's Third Quarter 2023 Earnings Conference Call. Today's conference is being recorded.
- 1(current)
- 2
What type of business is Bionano Genomics?
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
What sector is Bionano Genomics in?
Bionano Genomics is in the Healthcare sector
What industry is Bionano Genomics in?
Bionano Genomics is in the Medical Instruments & Supplies industry
What country is Bionano Genomics from?
Bionano Genomics is headquartered in United States
When did Bionano Genomics go public?
Bionano Genomics initial public offering (IPO) was on 21 August 2018
What is Bionano Genomics website?
https://www.bionanogenomics.com
Is Bionano Genomics in the S&P 500?
No, Bionano Genomics is not included in the S&P 500 index
Is Bionano Genomics in the NASDAQ 100?
No, Bionano Genomics is not included in the NASDAQ 100 index
Is Bionano Genomics in the Dow Jones?
No, Bionano Genomics is not included in the Dow Jones index
When does Bionano Genomics report earnings?
The next expected earnings date for Bionano Genomics is 09 August 2024